ArticleMicrobiology spectrum2025
A novel broad host range phage phiA85 displays a synergistic effect with antibiotics targeting carbapenem-resistant
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Antibiotic-induced cellular enlargement drives phage synergy and resensitizes carbapenem-resistantMicrobiology spectrum · 2026Article
- Biofilm-Mediated Antimicrobial Resistance in PediatricAntibiotics (Basel, Switzerland) · 2026Review
- Phage Therapy in Combating Multidrug-Resistant Gram-Negative Pathogens: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Prevalence, Virulence, and Pathogenic Mechanisms of Mastitis-AssociatedVeterinary sciences · 2026Review
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Phage therapy for multidrug-resistant pulmonary infections: bridging precision matching, lung delivery, host immunity, and clinical translation.Frontiers in cellular and infection microbiology · 2026Review
- Lytic bacteriophages targeting carbapenem-resistant Klebsiella pneumoniae isolated in a resource-limited Zambian laboratory.Access microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Carbapenem-resistant IMPORTANCE: The widespread prevalence of MDR bacteria has become a critical public health threat with limited therapeutic options. This study identifies a novel broad host range phage phiA85, capable of lysing strains across different KL types of CRKP. This characteristic addresses the limitation of narrow host range of capsular-specific phages, thereby significantly expanding their therapeutic potential against multidrug-resistant bacterial infections. Phage phiA85-antibiotic combinations achieve PAS, enhancing lytic activity and biofilm inhibition
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.